Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Net Sales in the U.S.: $35M in FY2025, up 25.0% from a year earlier.
Latest, FY2025
35
Period ended Dec 31, 2025
Change on a year earlier
+25.0%
28 in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below
Where the FY2025 figure comes from
“|| Diovan Group | Established brands | Hypertension | 35 | 25 | 569 | 1 | 1 | 604 | 2 | 2”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F (Top 20 Brands US / Rest of World).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net Sales in the U.S. ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 35 | +25.0% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 28 | -46.2% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2023 | Dec 31, 2023 | 52 | -5.5% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2022 | Dec 31, 2022 | 55 | +7.8% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2021 | Dec 31, 2021 | 51 | -58.9% | Novartis Form 6-K (0001370368-22-000009) ↗ |
| FY2020 | Dec 31, 2020 | 124 | +44.2% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2019 | Dec 31, 2019 | 86 | +2.4% | Novartis Form 6-K (0001370368-20-000007) ↗ |
| FY2018 | Dec 31, 2018 | 84 | – | Novartis Form 6-K (0001370368-19-000006) ↗ |
Breakdown
What makes up net Sales in the U.S.
Cite this data
StockData. (2026). Novartis Net Sales in the U.S. ($M), annual FY2018–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-diovan-group-us-sales
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.